
1. Windtree Therapeutics (OTC: WINT)
Windtree is a US biotech firm, headquartered in Pennsylvania, that was developing drugs and treatments for cardiovascular disorders. In July 2025, Windtree announced plans to build a BNB treasury, but its management decided not to go ahead with the strategy in August 2025, according to its quarterly report to the SEC. Nasdaq delisted Windtree’s shares in August 2025 and they now trade over the counter (OTC), and in December 2025 it agreed to sell its cardiovascular drug candidates.
Why BNB?
Windtree had planned to become one of the world’s first corporate BNB treasuries to diversify its treasury assets and offer shareholders exposure to the Binance ecosystem, but it dropped the plan in August 2025.



